 | ||
| Invitation to Access Expires at Midnight Zacks Member, Haven't heard from you about my Thursday email so I'm following up with an important message . . . Today you can still beat the deadline to download our Special Report, 5 Stocks Set to Double. Remember, these 5 were selected from thousands of companies. Each is the single favorite stock of a Zacks expert who gives it the best chance to gain +100% and more in the months ahead. Previous editions of this report have racked up some huge gains. Examples include Boston Beer Co. which soared +143.0%, Nvidia blasted +175.9%, Weight Watchers climbed +498.3%, and Tesla surged +673%.¹ Before word spreads too far, tomorrow morning looks like a very good time to buy these companies: Stock #1 - Shares of this Growing Tech Company Gained +113% Since March 2020. An American tech developer, with products already available in the Apple App Store and Google Play, that's pairing the prevalence of smartphone use with another sustainable growth industry. Fueled by a record quarter in Q3 2020, its shares have gained 270% over the last five years with more upside ahead. Stock #2 - Asian Company Controlling 80% of E-Comm's Market Share. With a seemingly endless number of digital products available, this multinational company is the most profitable in China. It controls 80% of e-comm's market share, and for the next few years, has a more extensive revenue growth outlook than Amazon. It has a massive amount of growth potential, and 15 out of 15 analysts call this a buy today. Stock #3 - Domestic Well-Diversified Construction Company on the Rise. This diversified construction company specializes in providing various services for the traditional power, civil infrastructure, and renewable energy industries. Last quarter, the company doubled Zacks earnings per share estimates, and it's poised to benefit significantly from the clean energy plan to be initiated by the new presidential administration. Stock #4 - Small-Cap Biotech Company Poised for Explosive Growth. An emerging player in the field of central nervous system disorders, this biopharmaceutical company focuses on treating certain neurological diseases using its innovative proprietary platform. Analysts are already bullish due to the company's potential for treating Alzheimer's and Rett syndrome. Stock #5 - Renowned Omnichannel Retailer Wisely Pivots During Pandemic. Thanks to its omnichannel platforms and e-commerce presence, this retailer is already a household name in most states. In-store sales have increased 23.2% year-over-year. E-comm sales recorded an impressive 95% increase. Shares have soared approximately 290% since their March 2020 lows with the strong possibility of serious future gains. 5 Stocks Set to Double is yours free when you start 30-day access to the Zacks Investor Collection program which includes all our private long-term buys & sells for a total of $1. You may cancel at any time and there's no obligation to spend another cent. Why only $1 for Zacks Investor Collection? I just want to encourage you to sample our real-time moves from stocks under $10 to home run investments to income recommendations. Plus, Zacks Premium research and tools to find and evaluate your own stocks, ETFs and mutual funds. Please keep in mind that this opportunity is ending fast. Be sure to download the free report before midnight tonight, January 31. Happy Investing,
| ||
 | ||
| ¹The results are not (or may not be) representative of the performance of all selections made by Zacks Investment Research's newsletter editors. This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or US investment adviser or investment bank. The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through January 6, 2020. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank #1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed above. Zacks Emails Zacks Investment Research |
没有评论:
发表评论